Nirsevimab: A Promising Therapy for RSV

• 2022

  Log in to bookmark this resource.

  Log in
• Priya Venkatesan
PMID: 35544094DOI: https://doi.org/10.1016/S2666-5247(22)00097-0

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article describes nirsevimab as a new treatment for RSV, a virus causing severe lung infections in children. Unlike the older drug palivizumab, which needs five doses, nirsevimab requires just one shot before RSV season. A study showed it reduced RSV-related illnesses by 75% but didn't significantly lower hospital visits. Experts believe it could protect infants better than current treatments and suggest combining it with vaccines for long-term protection. Until more options are available, good hygiene practices like hand washing are important to prevent RSV spread and protect young children from future lung problems.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Immunization, Passive; Infant; Infant, Newborn; Respiratory Syncytial Virus Infections; Palivizumab

Institutions: The Lancet

---

More like this

Respiratory Syncytial Virus Vaccines: The Future is Bright 2024 · The Lancet Mpox: The Need for a Coordinated International Response 2024 · The Lancet Oral Rehydration, Emergency Physicians, and Practice Parameters: A National Survey 2002 · Children's Hospital at Montefiore

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---